RPTX - Repare Therapeutics continues climb following Roche licensing deal; shares up 40%

Repare Therapeutics (NASDAQ:RPTX) is continuing to benefit Thursday from a licensing deal with Roche (OTCQX:RHHBY) announced after the closing bell Wednesday. In afternoon trading, shares are up ~40%. Under the terms, Repare (RPTX) is receiving $125M in upfront payments and up to $1.2 billion in milestone payments as Roche (OTCQX:RHHBF) takes over development of RP-3500 for advanced solid tumors. The candidate is an inhibitor of the ATR protein. Despite today's gains, Repare (RPTX) is still down ~45% year to date. Seeking Alpha's Quant Rating views Repare (RPTX) as a strong sell.

For further details see:

Repare Therapeutics continues climb following Roche licensing deal; shares up 40%